Michele M Mumaw1, Maria de la Fuente1, Amal Arachiche1, James K Wahl2, Marvin T Nieman3. 1. Department of Pharmacology, Case Western Reserve University, Cleveland, OH, USA. 2. Department of Oral Biology, College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, USA. 3. Department of Pharmacology, Case Western Reserve University, Cleveland, OH, USA. Electronic address: nieman@case.edu.
Abstract
BACKGROUND: Protease activated receptor 4 (PAR4) is a G protein coupled receptor (GPCR) which is activated by proteolytic cleavage of its N-terminal exodomain. This generates a tethered ligand that activates the receptor and triggers downstream signaling events. With the current focus in the development of anti-platelet therapies shifted towards PARs, new reagents are needed for expanding the field's knowledge on PAR4. Currently, there are no PAR4 reagents which are able to detect activation of the receptor. METHODS: Monoclonal PAR4 antibodies were purified from hybridomas producing antibody that were generated by fusing splenocytes with NS-1 cells. Immunoblotting, immunofluorescence, and flow cytometry were utilized to detect the epitope for each antibody and to evaluate the interaction of the antibodies with cells. RESULTS: Here, we report the successful generation of three monoclonal antibodies to the N-terminal extracellular domain of PAR4: 14H6, 5F10, and 2D6. We mapped the epitope on PAR4 of 14H6, 5F10, and 2D6 antibodies to residues (48-53), (41-47), and (73-78), respectively. Two of the antibodies (14H6 and 5F10) interacted close to the thrombin cleavage and were sensitive to α-thrombin cleavage of PAR4. In addition, 5F10 was able to partially inhibit the cleavage of PAR4 expressed in HEK293 cells by α-thrombin. CONCLUSIONS: These new antibodies provide a means to monitor endogenous PAR4 expression and activation by proteases on cells.
BACKGROUND:Protease activated receptor 4 (PAR4) is a G protein coupled receptor (GPCR) which is activated by proteolytic cleavage of its N-terminal exodomain. This generates a tethered ligand that activates the receptor and triggers downstream signaling events. With the current focus in the development of anti-platelet therapies shifted towards PARs, new reagents are needed for expanding the field's knowledge on PAR4. Currently, there are no PAR4 reagents which are able to detect activation of the receptor. METHODS: Monoclonal PAR4 antibodies were purified from hybridomas producing antibody that were generated by fusing splenocytes with NS-1 cells. Immunoblotting, immunofluorescence, and flow cytometry were utilized to detect the epitope for each antibody and to evaluate the interaction of the antibodies with cells. RESULTS: Here, we report the successful generation of three monoclonal antibodies to the N-terminal extracellular domain of PAR4: 14H6, 5F10, and 2D6. We mapped the epitope on PAR4 of 14H6, 5F10, and 2D6 antibodies to residues (48-53), (41-47), and (73-78), respectively. Two of the antibodies (14H6 and 5F10) interacted close to the thrombin cleavage and were sensitive to α-thrombin cleavage of PAR4. In addition, 5F10 was able to partially inhibit the cleavage of PAR4 expressed in HEK293 cells by α-thrombin. CONCLUSIONS: These new antibodies provide a means to monitor endogenous PAR4 expression and activation by proteases on cells.
Authors: Seema Dangwal; Bernhard H Rauch; Thomas Gensch; Luru Dai; Ellen Bretschneider; Christina Francisca Vogelaar; Karsten Schrör; Anke C Rosenkranz Journal: Arterioscler Thromb Vasc Biol Date: 2010-12-16 Impact factor: 8.311
Authors: Leonard C Edelstein; Lukas M Simon; Raúl Teruel Montoya; Michael Holinstat; Edward S Chen; Angela Bergeron; Xianguo Kong; Srikanth Nagalla; Narla Mohandas; David E Cohen; Jing-fei Dong; Chad Shaw; Paul F Bray Journal: Nat Med Date: 2013-11-10 Impact factor: 53.440
Authors: Shauna L French; Claudia Thalmann; Paul F Bray; Lynn E Macdonald; Andrew J Murphy; Mark W Sleeman; Justin R Hamilton Journal: Blood Adv Date: 2018-06-12
Authors: Thomas H Smith; Luisa J Coronel; Julia G Li; Michael R Dores; Marvin T Nieman; JoAnn Trejo Journal: J Biol Chem Date: 2016-07-11 Impact factor: 5.157
Authors: Anh T P Ngo; Jawaad Sheriff; Anne D Rocheleau; Matthew Bucher; Kendra R Jones; Anna-Liisa I Sepp; Lisa E Malone; Amanda Zigomalas; Alina Maloyan; Wadie F Bahou; Danny Bluestein; Owen J T McCarty; Kristina M Haley Journal: Platelets Date: 2019-02-27 Impact factor: 3.862
Authors: M J Whitley; D M Henke; A Ghazi; M Nieman; M Stoller; L M Simon; E Chen; J Vesci; M Holinstat; S E McKenzie; C A Shaw; L C Edelstein; P F Bray Journal: J Thromb Haemost Date: 2018-11-22 Impact factor: 5.824
Authors: Martin J Scott; Amanda Jowett; Martin Orecchia; Peter Ertl; Larissa Ouro-Gnao; Julia Ticehurst; David Gower; John Yates; Katie Poulton; Carol Harris; Michael J Mullin; Kathrine J Smith; Alan P Lewis; Nick Barton; Michael L Washburn; Ruud de Wildt Journal: MAbs Date: 2020 Jan-Dec Impact factor: 5.857
Authors: Benjamin E Tourdot; Hannah Stoveken; Derek Trumbo; Jennifer Yeung; Yogendra Kanthi; Leonard C Edelstein; Paul F Bray; Gregory G Tall; Michael Holinstat Journal: Arterioscler Thromb Vasc Biol Date: 2018-05-10 Impact factor: 8.311